News
AbbVie’s telisotuzumab dizutecan achieved an ORR of 63% in EGFR-mutant NSCLC patients, with current ADC options in this ...
MedPage Today on MSN22h
New Preoperative Regimen Gets a Win in Pancreatic CancerCHICAGO -- A neoadjuvant chemotherapy regimen of cisplatin (Platinol), nab-paclitaxel (Abraxane), capecitabine (Xeloda), and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback